â– LECTURE OVERVIEW: Benign Prostatic Hyperplasia (BPH) is an age-related, non-malignant proliferation of the prostatic stromal and epithelial cells.
â– PATHWAY ANALYSIS:
1. Transition Zone: Hyperplasia occurs selectively in the central periurethral Transition Zone, compressing the prostatic urethra and obstructing urine outflow.
2. Dihydrotestosterone (DHT) Influence: Driven by DHT, synthesized from testosterone by 5-alpha-reductase in prostatic stromal cells.
3. Lower Urinary Tract Symptoms (LUTS): Presents with urinary frequency, urgency, nocturia, a weak urinary stream, hesitancy, and incomplete emptying.
4. Pharmacotherapy Approaches:
- Alpha-1 Adrenergic Blockers: Selectively block alpha-1A receptors on the prostatic urethra and bladder neck, relaxing smooth muscle to rapidly improve urine flow.
- 5-Alpha-Reductase Inhibitors: Block 5-alpha-reductase, preventing testosterone's conversion to DHT to shrink the prostate over 6-12 months.
â– SURGICAL LANDMARKS & ANATOMICAL BOUNDARIES:
Intraoperative access requires meticulous dissection along defined tissue planes. Avoid excessive traction near neurovascular bundles and look for key bony landmarks or fascial reflections to secure margins.
â– ACUTE TOXICOLOGICAL PROFILE:
High cumulative chemical exposure or accidental overdose triggers systemic receptor overload, cellular injury, and metabolic acidosis.
[HY-BOARD-1173]
🌟 Dynamic Clinical Key:
Alpha-1 blockers (e.g., Tamsulosin, Silodosin) provide rapid symptom relief but do not shrink the prostate. 5-alpha-reductase inhibitors (e.g., Finasteride, Dutasteride) are used for long-term reduction of prostate size, helping to prevent acute urinary retention. Never divide or ligate any vessel before clearly isolating and confirming its origin and termination. Immediate administration of physiological charcoal or specific receptor antagonists is lifesaving.